Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study (BLIS)
Primary Purpose
Iron-deficiency Anemia, Iron-deficiency
Status
Completed
Phase
Not Applicable
Locations
Ghana
Study Type
Interventional
Intervention
Iron Supplementation
Sponsored by
About this trial
This is an interventional other trial for Iron-deficiency Anemia focused on measuring Blood donation
Eligibility Criteria
Inclusion Criteria:
- Males or females aged between 17 and 60 years who weigh at least 50kg.
- Pass pre-donation screening using the NBSG standardised donor screening questionnaire for medical conditions and lifestyle risks for transfusion transmissible infections
- Vital signs must meet the NBSG requirement for blood donation: systolic and diastolic blood pressures between 90-140 mmHg and 60- 90 mmHg, respectively; pulse rate between 50-100 bpm; non-contact forehead temperature not exceeding 37.5°C; meeting acceptable requirements for skin lesions, needle marks and physical appearance.
- Must be willing and able to give study consent or assent.
- Intend to remain in the study location/site during the entire length of the study.
Exclusion Criteria:
- Persons who have used iron supplementation within the past one month.
- Participant reports having previously donated blood.
- Evidence for a TTI at baseline among those who successfully donated.
- Evidence of Malaria and helminthic infections at baseline
- Participants who have Hb <10g/dl at screening
Sites / Locations
- University of Ghana Medicial School, Department of Haematology
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Iron Supplementation
Control
Arm Description
Outcomes
Primary Outcome Measures
Haemoglobin level
Secondary Outcome Measures
Full Information
NCT ID
NCT04949165
First Posted
June 25, 2021
Last Updated
June 22, 2023
Sponsor
University of Minnesota
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), National Blood Service Ghana, University of Ghana Medical School, Liverpool School of Tropical Medicine, Syracuse University
1. Study Identification
Unique Protocol Identification Number
NCT04949165
Brief Title
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Acronym
BLIS
Official Title
Iron Supplementation and Nutritional Counseling Interventions to Improve Availability and Safety of Blood in Ghana
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
September 7, 2021 (Actual)
Primary Completion Date
May 31, 2023 (Actual)
Study Completion Date
May 31, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), National Blood Service Ghana, University of Ghana Medical School, Liverpool School of Tropical Medicine, Syracuse University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This pilot study has 2 components: 1) a cross-sectional assessment designed to estimate the prevalence of anaemia leading to donor deferral, the prevalence of iron deficiency (ID) and iron deficiency anaemia (IDA) among first-time donors, and 2) a longitudinal 2-arm parallel groups trial among first- time voluntary donors that compares haemoglobin levels at 4 months among those with ID or IDA who receive iron supplementation to those without ID or IDA who do not receive iron supplementation. A structured questionnaire will be used to extract demographic characteristics. Participants will be followed for a total of 6 months with study visits at 2, 4 and 6 months after the baseline assessments. Blood draws for full blood count (FBC), peripheral film comment, malaria rapid diagnostic tests (RDT) and ferritin assessment will occur at baseline and all follow-up visits. In addition, we will use a qualitative approach to identify barriers and facilitators of blood donation and the use of dietary and iron supplementation strategies to address iron deficiency and/or anaemia. This will involve conducting focus group discussions during the last month of the intervention and key informant interviews.
Expected Outcomes The expected outcomes of the study have been grouped into two, primary and secondary. Primary Outcome will be haemoglobin level after 4 months. Secondary Outcomes are A. Change in haemoglobin levels B. Diagnosis of ID or IDA at 4 months C. Serum ferritin concentration after 4 months of intervention D. Acceptability of iron supplementation among participants and stakeholders E. Incidence of gastrointestinal adverse events F. Incidence of suspected malaria or bacterial infections G. Incidence of ID and IDA H. Successful return (non-deferred) to the blood donor pool after intervention within 6 months of enrolment I. Key barriers and facilitators of intervention implementation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iron-deficiency Anemia, Iron-deficiency
Keywords
Blood donation
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
223 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Iron Supplementation
Arm Type
Experimental
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Iron Supplementation
Intervention Description
low dose ferrous sulphate (65mg elemental iron) supplements
Primary Outcome Measure Information:
Title
Haemoglobin level
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
17 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males or females aged between 17 and 60 years who weigh at least 50kg.
Pass pre-donation screening using the NBSG standardised donor screening questionnaire for medical conditions and lifestyle risks for transfusion transmissible infections
Vital signs must meet the NBSG requirement for blood donation: systolic and diastolic blood pressures between 90-140 mmHg and 60- 90 mmHg, respectively; pulse rate between 50-100 bpm; non-contact forehead temperature not exceeding 37.5°C; meeting acceptable requirements for skin lesions, needle marks and physical appearance.
Must be willing and able to give study consent or assent.
Intend to remain in the study location/site during the entire length of the study.
Exclusion Criteria:
Persons who have used iron supplementation within the past one month.
Participant reports having previously donated blood.
Evidence for a TTI at baseline among those who successfully donated.
Evidence of Malaria and helminthic infections at baseline
Participants who have Hb <10g/dl at screening
Facility Information:
Facility Name
University of Ghana Medicial School, Department of Haematology
City
Accra
Country
Ghana
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
The BLOODSAFE project is committed to quickly sharing results and data. Papers will be submitted summarizing the primary results of the BLOODSAFE studies once the analysis is complete. These results will be published in major scientific journals and presented at scientific meetings.
Learn more about this trial
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
We'll reach out to this number within 24 hrs